Proactive Investors - Run By Investors For Investors
Why invest in NANO?

Nanobiotix technology has "blockbuster potential", according to American investment bank

Nanoparticles with mega potential - that’s how the biotech team at American investment bank described the company's technology
Patient undergoing radiotherapy
The breakthrough amplifies the effect of radiotherapy

Nanoparticles with mega potential - that’s how the biotech team at American investment bank Jefferies described Nanobiotix SA (EPA:NANO), which has developed a unique method of amplifying radio-therapy.

Jefferies Wednesday initiated coverage of stock in the company with a ‘buy’ rating and €26 a share price target. That’s 32% above the current price of €19.66.

The company has developed NBTXR3, which is injected directly into solid tumours to amplify the effects of tumour shrinking treatment.

It has already demonstrated success tackling soft tissue sarcoma, a cancer that affects muscle, fat and blood vessels.

Seven cancers...

It is now being trialled across seven separate cancer indications.

Analyst Peter Welford believes the treatment has “blockbuster potential” if is widely adopted.

“As a one-time treatment that is fully compatible with standard radiotherapy protocols, NBTXR3 could be used in around 60% of radiotherapy-treated cancers,” he said.

The analyst estimates worldwide peak sales for use in soft tissue sarcoma (STS) could be in the order of US$175mln, while head and neck cancer is a far bigger market for Nanobiotix at US$550mln a year.

Other uses...

However, the product could generate US$1.4bn a year for the business if it is more widely adopted, Welford reckons.

The current valuation only takes into account NBTXR3’s use in STS and head and neck cancer.

“NBTXR3 could also act as an in situ vaccine with radiotherapy to aid transforming tumours from ‘cold’ to ‘hot’ with highly immunogenic targets, suggesting a potentially lucrative combo with immuno-oncology agents,” the analyst pointed out.

View full NANO profile View Profile

Nanobiotix SA Timeline

Related Articles

worried man on bed
October 16 2017
“We are delighted by the results of this new survey, which not only reinforce the potential of MED2002 identified in our two earlier surveys but provide some important additional insights”
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use